ruxolitinib’s place in the future treatment landscape for mpns
Published 3 years ago • 68 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:52
the role of ruxolitinib in the treatment of early-stage myelofibrosis
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
7:17
natural treatment for itp - idiopathic thrombocytopenic purpura | a platelet disorder
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
2:54
ruxolitinib in the real world: myelofibrosis
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
0:53
defining suboptimal response to ruxolitinib and the strategy for switching treatments
-
1:44
predicting thrombocytopenia as a result of ruxolitinib treatment in mf
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
1:01
clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial